Apricus Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.04.24	Seelos Therapeutics Appoints Richard Pascoe As Chairman Of The Board (RTTNews)
19.03.24	Seelos: Phase 2/3 HEALEY ALS Trial Fails To Meet Statistical Significance In Endpoints (RTTNews)
26.01.24	Seelos Therapeutics Announces $4 Mln Direct Offering And Private Placement Of Shares (RTTNews)
22.01.24	Seelos Therapeutics Says Received Minutes From End Of Phase II Meeting With FDA (RTTNews)
02.01.24	Seelos Therapeutics: ISS Recommends Stockholders Vote For All Proposals - Quick Facts (RTTNews)
02.01.24	Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024 (PR Newswire)
22.12.23	Seelos Therapeutics, Inc. Releases Letter to its Stockholders (PR Newswire)
01.12.23	Seelos Therapeutics Announces Closing of Public Offering (PR Newswire)
29.11.23	Seelos Therapeutics Announces Pricing Of $5.55 Mln Public Offering; Stock Drops (RTTNews)
29.11.23	Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering (PR Newswire)
29.11.23	Seelos Therapeutics Commences Underwritten Public Offering Of Shares (RTTNews)
28.11.23	Seelos Therapeutics Announces Proposed Public Offering (PR Newswire)
27.11.23	Seelos' SLS-002 To Be Included In DOD's Trial To Evaluate Potential Treatments For PTSD (RTTNews)
27.11.23	Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for ... (PR Newswire)
24.11.23	Seelos Therapeutics Announces 1-for-30 Reverse Stock Split (PR Newswire)
27.10.23	Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023 (PR Newswire)
17.10.23	Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations (PR Newswire)
27.09.23	Seelos Announces Encouraging Data From Study Of SLS-005 In Preclinical Model Of Alzheimer's Disease (RTTNews)
27.09.23	Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease (PR Newswire)
21.09.23	Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock (PR Newswire)
20.09.23	Seelos Therapeutics: SLS-002 Phase II Study Fails To Meet Primary Endpoint On Limited Sample Size (RTTNews)
20.09.23	Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide (PR Newswire)
14.08.23	Seelos Therapeutics Provides Second Quarter 2023 Clinical Update (PR Newswire)
22.06.23	Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Maj... (PR Newswire)
22.05.23	Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences (PR Newswire)
15.05.23	Seelos Therapeutics, Inc Q1 Loss decreases, but misses estimates (RTTNews)
15.05.23	Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results (PR Newswire)
05.05.23	Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting (PR Newswire)
04.04.23	Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program (PR Newswire)
29.03.23	Seelos Therapeutics Announces Business Update on its Key Programs (PR Newswire)
10.03.23	Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock (PR Newswire)
15.02.23	Seelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference (PR Newswire)
13.02.23	Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform (PR Newswire)
10.02.23	Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit (PR Newswire)
06.02.23	Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine) (PR Newswire)
22.12.22	Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event (PR Newswire)
15.12.22	Seelos: In Vivo Data Shows Potential Of SLS-004 As Disease-modifying Gene Therapy In Parkinson's (RTTNews)
15.12.22	Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease (PR Newswire)
08.12.22	Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022 (PR Newswire)
23.11.22	Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022 (PR Newswire)
07.11.22	Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day (PR Newswire)
27.10.22	Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event (PR Newswire)
25.10.22	Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia (PR Newswire)
30.09.22	Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the A... (PR Newswire)
13.09.22	Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patient... (PR Newswire)
09.09.22	Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference (PR Newswire)
30.08.22	Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences (PR Newswire)
24.08.22	Seelos Receives R&D Grant From Michael J. Fox Foundation For Parkinson's Research For SLS-004 (RTTNews)
24.08.22	Seelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004 (PR Newswire)
18.07.22	Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novartis	95.58	1.90 %	K V
Logitech Intl	91.48	1.35 %	K V
Part Grp Hldg	1’393.00	1.20 %	K V
Roche Hldg G	286.00	0.28 %	K V
Sonova Hldg	319.20	0.16 %	K V
Swiss Re	139.40	-0.50 %	K V
Zurich Insur Gr	553.80	-0.54 %	K V
Kuehne+Nagel Int	207.60	-0.76 %	K V
Lonza Grp	582.00	-1.49 %	K V
Nestle	77.48	-1.53 %	K V

Nachrichten zu Apricus Biosciences Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten